In November, USD/IDR continued fluctuating without moving in any direction. In December, the Indonesian rupiah is likely to remain weak against the US dollar. This is due to the progress on global economic recovery being slowed by the detection of the omicron variant, economists at Mizuho Bank report.
Uncertain elements regarding the omicron variant to keep the market unstable in the near-term
“The omicron variant is only likely to lead the USD/IDR to fluctuate from a short-term perspective. From a medium to long-term perspective, the Indonesian rupiah is likely to weaken, regardless of whether or not the variant will become a threat to daily life and the global economy.”
“The October trade surplus of Indonesia recorded its largest trade surplus on a single-month basis. If the situation remains the same, it would keep the Indonesian rupiah exchange rate from falling further. However, commodity prices could fall significantly, depending on the situation related to the omicron variant of covid.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.